Filing Flows › Assembly Biosciences (ASMB) › Q1 2025
Assembly Biosciences (ASMB) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Assembly Biosciences (ASMB) reported revenue of $9.4M for the first quarter 2025 (Q1 2025), +63% from a year earlier and +28% from the quarter before. Operating margin was -105.5%, net loss $8.8M (93.6% of revenue).
Assembly Biosciences, Q1 2025: revenue $9.4M (+63% year over year), operating margin -105.5%, net loss $8.8M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.4M | +28% | +63% |
| Operating profit | −$9.9M | — | — |
| Net earnings | −$8.8M | — | — |
| Operating cash flow | −$23.4M | — | — |
What changed
Revenue was $9.4M in Q1 2025, up 63% year over year and up 28% from the previous quarter.
Operating costs exceeded revenue by $9.9M, an operating margin of -105.5%. Total costs grew 17% against revenue growth of 63%. The fastest-growing cost line was Research & development (+25%). The quarter ended with a net loss of $8.8M, narrower than the previous quarter's $10.3M loss.
Operating cash flow was −$23.4M. Non-cash charges added back $33K of depreciation and amortization and $712K of share-based compensation. Working capital and other items used $15.4M.
Questions
What was Assembly Biosciences' revenue in the first quarter 2025?
Assembly Biosciences (ASMB) reported revenue of $9.4M for the first quarter 2025 (Q1 2025), +63% from a year earlier and +28% from the quarter before.
Was Assembly Biosciences profitable in the first quarter 2025?
Operating loss was $9.9M (-105.5% of revenue) and net loss $8.8M.